Anastassia Anastassopoulou

Anastassia Anastassopoulou

Auto-generated profile, based on publicly available information

Anastassia Anastassopoulou

Market Access, Daiichi Sankyo Europe GmbH, München, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Vaccine
Verified
Journal Article
Open access
CPChristine Poulos
Christine Poulos
DCDesmond Curran
Desmond Curran
AAAnastassia Anastassopoulou
Anastassia Anastassopoulou
LMLaurence De Moerlooze
Laurence De Moerlooze
Many travelers to regions with endemic infectious diseases do not follow health authorities' recommendations regarding vaccination against vaccine-preventable infectious diseases, before traveling. The determinants of individual travelers' decisions to vaccinate before traveling are largely unknown. This study aimed to provide this information using a discrete choice experiment (DCE) administered to four types of German travelers: (1) business travelers; (2) travelers visiting friends and relatives (VFR); (3) leisure travelers; and (4) backpackers. A DCE survey was developed, pretested and administered online. It included a series of choice questions in which respondents chose between two hypothetical vaccines, each characterized by four disease attributes with varying levels describing the of risk, health impact, curability and transmissibility of the disease they would prevent (described with four disease attributes with varying levels of risk, health impact, curability and transmissibility), and varying levels of four vaccine attributes (duration of protection, number of doses required, time required for vaccination, and vaccine cost). A random-parameters logit model was used to estimate the importance weights each traveler type placed on the various attribute levels. These weights were used to calculate mean monetary equivalents (MMEs) of changes in each attribute (holding all others constant) and of hypothetical disease-vaccine combinations. All traveler types' choices indicated that they attached the greatest importance to the risk and health impact of disease and to the vaccine cost whereas the other disease and vaccine attributes were less important for their decisions about travel vaccines. An option of not choosing any of the vaccine-pairs presented was rarely selected indicating that travelers' generally prefer to be vaccinated rather than not. The MMEs of changes in vaccine attributes indicated a very high variability between the individual travelers within each type. The travelers' responses indicated strong preferences for selecting vaccination rather than opting out of vaccination, and disease risk, health impact and vaccine cost were the most important features for vaccine choice.

29 April 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
DMDaniel Molnar
Daniel Molnar
AAAnastassia Anastassopoulou
Anastassia Anastassopoulou
BNBarbara Poulsen Nautrup
Barbara Poulsen Nautrup
RSRuprecht Schmidt-Ott
Ruprecht Schmidt-Ott
MEMartin Eichner
Martin Eichner
LBLaure-Anne Van Bellinghen
Laure-Anne Van Bellinghen
Seasonal influenza causes many cases and related deaths in Europe annually, despite ongoing vaccination programs for older adults and people at high-risk of complications. Children have the highest risk of infection and play a key role in disease transmission. Our cost-utility analysis, based on a dynamic transmission model, estimated the impact of increasing the current vaccination coverage with inactivated quadrivalent influenza vaccine in Germany to all (healthy and high-risk) children under 5 years of age (40% uptake), or under 18 years (40% uptake), or only high-risk children under 18 years (90% uptake). Eight influenza complications were modeled, hospitalization and death rates were based on age and risk status. All three vaccination strategies provided more health benefits than the existing vaccination situation, reducing influenza cases, complications, hospitalizations and deaths across the entire population. The strategy targeting all children under 5 years was highly cost-effective (€6/quality-adjusted life-year gained, payer perspective). The other strategies were cost saving from the payer and societal perspectives. The vaccination strategy targeting all children under 18 years was estimated to provide the most health benefits (preventing on average 1.66 million cases, 179,000 complications, 14,000 hospitalizations and 3,600 deaths due to influenza annually) and the most cost savings (annually €20.5 million and €731.3 million from payer and societal perspectives, respectively). Our analysis provides policy decision-makers with evidence supporting strategies to expand childhood influenza vaccination, to directly protect children, and indirectly all other unvaccinated age groups, in order to reduce the humanistic and economic burden on healthcare systems and society. What is the context? What is new? What is the impact?

14 October 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
EHEdith M. Heintjes
Edith M. Heintjes
AAAnastassia Anastassopoulou
Anastassia Anastassopoulou
JKJosephina Kuiper
Josephina Kuiper
ABAikaterini Bilitou
Aikaterini Bilitou
FBFernie J. A. Penning-Van Beest
Fernie J. A. Penning-Van Beest
JJJ. Wouter Jukema
J. Wouter Jukema
Objective: To describe treatment patterns, low-density lipoprotein cholesterol (LDL-C) levels and healthcare resource utilization (HCRU) in the Netherlands in 2018 of patients with hypercholesterolaemia or mixed dyslipidaemia at high or very high cardiovascular (CV) risk. Methods: From the PHARMO Database Network adult patients with a diagnosis for hypercholesterolaemia or mixed dyslipidaemia or treated with lipid lowering therapy (LLT) between 2009 and 2018 were selected and the proportion at high or very high CV risk according to 2016 ESC/EAS guidelines was determined. The study population comprised patients at high or very high CV risk for whom LDL-C levels were recorded and who were treated with LLT or were characterized as statin intolerant in 2018. LLT treatment patterns, LDL-C levels and HCRU (GP consultations and hospitalizations) were assessed. Results: The study population included 54,346 patients with hypercholesterolaemia/mixed dyslipidaemia, of which 70% (37,978) were at very high CV risk and 30% (16,368) at high CV risk. The majority of patients (93%) were treated with statin monotherapy, consisting mostly (73%) of moderate intensity and 15% of high intensity statin. Only 3% were treated with a combination of statin and ezetimibe. Statin intolerance, based on a treatment algorithm, was estimated at 3%. Average LDL-C decreased with intensification of LLT with more intensive statins or combination therapy. Overall, 74% reached LDL-C <2.5 mmol/l and 34% <1.8 mmol/l with their current treatment, and 46% reached their LDL-C goal according to 2016 ESC/EAS guidelines. The highest rates of hospitalizations and GP consultations, including home visits, were recorded in patients with peripheral artery disease or polyvascular disease. Conclusion: The treatment of hypercholesterolaemia and mixed dyslipidaemia in patients at high or very high CV risk in the Netherlands was suboptimal in 2018. To further lower CV risk alternative treatment strategies using add-on therapies are needed.

29 August 2023 in Atherosclerosis
Verified
Journal Article
Open access
CGCristina Gavina
Cristina Gavina
CTC. Teixeira
C. Teixeira
JRJ. Ruivo
J. Ruivo
AAA. Anastassopoulou
A. Anastassopoulou
MCM. Canelas-Pais
M. Canelas-Pais
Tiago Taveira-GomesTiago Taveira-Gomes
Tiago Taveira-Gomes